

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT “PIRACETAM INJECTION” APPROVED FOR MARKETING

The board (the “**Board**”) of directors (the “**Directors**”) of Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “Piracetam Injection” (吡拉西坦注射液), developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Group, has obtained the approval for marketing from the National Medical Products Administration of the PRC* (國家藥品監督管理局). The product is approved for the treatment of memory impairment and mild to moderate cerebral dysfunction caused by various conditions, including acute and chronic cerebrovascular diseases, traumatic brain injury and various toxic encephalopathies. It may also be applied to children with delayed intellectual development.

“Piracetam Injection” is a cerebral metabolism-enhancing agent and the first member of the “racetam” class of drugs developed based on the structure of the inhibitory neurotransmitter γ -aminobutyric acid (GABA). It activates the adenylate kinase enzyme, which increases the ATP/ADP ratio in the brain, thereby enhancing the brain’s absorption and utilization of amino acids, proteins and glucose. It also promotes cerebral cellular metabolism and increases the resistance of the cerebral cortex to hypoxia. In addition, *in vitro* studies have shown that piracetam can exert a protective effect on mitochondrial functions, such as protecting mitochondria from oxidative stress.

As a cerebral metabolism-enhancing medicine, piracetam has been widely used in clinical practice due to its significant therapeutic efficacy and minimal side effects. For the treatment of Alzheimer’s disease, it is recommended by the *Chinese Guideline for Diagnosis and Treatment of Dementia and Cognitive Disorders* (《中國癡呆與認知障礙診治指南》) and the *Expert Consensus on the Diagnostic and Treatment Pathway for Cognitive Impairment in the Elderly in China* (《中國老年人認知障礙診治流程專家意見》). Its neuroprotective effects have also been included in the *Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke* (《中國急性缺血性腦卒中診治指南》), and it is a recommended medication under the *Expert Consensus on Clinical Management of Post-stroke Aphasia* (《卒中後失語臨床管理專家共識》).

This product is a Class B drug under the National Healthcare Security Administration of the PRC. According to data from Menet, the sales of Piracetam Injection in China's three major terminal channels and six key markets exceeded RMB250 million in 2025. The Piracetam Injection (20ml: 8mg) specification developed by the Group has been in the PRC domestic market for many years and has gained a relatively high level of market recognition. The additional specifications approved under the current application, namely 5ml: 1mg and 15ml: 3mg, will further cater to the clinical treatment needs of different patient groups.

“Piracetam Injection” is another important product of the Group, which further enriches the Group's product pipeline in the field of neurological disorders. The marketing of this product will provide more treatment options for patients suffering from cerebrovascular diseases and cognitive impairment.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 16 June 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.

* *For identification purposes only.*